The World Health Organization (WHO) has placed snake envenomations as a global health concern causing 84,000-138,000 deaths yearly. The WHO’s strategy for snake envenoming is to reduce mortality and morbidity by 50% by 2030. One way to meet this objective includes producing safe and effective treatments for snakebites. Much of the detailed mechanism of action of snake envenomation is still not well understood. Developing new targeted therapies to mitigate snakebites remains an area of high medical interest. In the next grant period, the NNTRC’s Applied Research Program will be focused on exploring the innate resistance of opossums and woodrats to help develop the next generation of antivenoms by identifying key components that play a role in this resistance. The NNTRC’s Applied Research Program will also continue to provide resources to support the improvement of the products and services that the NNTRC provides to its user community. The NNTRC will continue to focus on the application of new methods and approaches to the production of medically significant recombinant snake venom toxins and the development of novel cell-based assays that can be used for the testing of antivenoms and toxin inhibitory molecules that can have a transformative impact on the treatment of snakebites.